Infliximab in the treatment of rheumatoid arthritis

Authors: Augustsson, Jenny; Jonsdottir, Thorunn; Klareskog, Lars; van Vollenhoven, Ronald F

Source: Aging Health, Volume 2, Number 1, February 2006 , pp. 19-33(15)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Rheumatoid arthritis is a chronic inflammatory systemic autoimmune disorder characterized by symmetric inflammation of synovial joints, leading to progressive erosion of cartilage and bone. Tumor necrosis factor-α antagonists have set a new therapeutic standard for rheumatoid arthritis. Tumor necrosis factor-α blocking agents, including infliximab, etanercept and adalimumab, have demonstrated substantial improvement in signs and symptoms, disability and quality of life, while significantly inhibiting joint damage in early and long-standing rheumatoid arthritis. The focus of this article will be the role of infliximab in the treatment of rheumatoid arthritis.

Keywords: autoimmune; elderly; inflammation; infliximab; rheumatoid arthritis; tumor necrosis factor

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/1745509X.2.1.19

Publication date: 2006-02-01

More about this publication?

Aging Health leading coverage of current and emerging topics relating to the safe and effective management of therapy in the elderly, all subject to rigorous peer review. The journal focuses on the most important advances and highlights their relevance in the clinical setting. The journal has been designed to deliver essential concise information in an easily assimilable format - vital for the increasingly time-constrained professional.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites